Research from Atrium Research, Atrium Research Corporation

Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis.

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>Cannara has maintained a solid growth trajectory, with expectations of ~20% going forward through its measured expansion plan.</li>
<li>The Company has best-in-class profitability with adjusted EBITDA margins of 29%, benefiting from its footprint in Quebec.</li>
<li>The launch of vape products in Quebec will serve as a growth driver for the Quebec segment, while distribution expands in the other provinces.</li>
</ul>


Cannara has maintained a solid growth trajectory, with expectations of ~20% going forward through its measured expansion plan.
The Company has best-in-class profitability with adjusted EBITDA margins of 29%, benefiting from its footprint in Quebec.
The launch of vape products in Quebec will serve as a growth driver for the Quebec segment, while distribution expands in the other provinces.


LOVE: Scalable Facilities, Record Profitability, and Re-Rating Potential

Cannara Biotech

LOVE: Scalable Facilities, Record Profitability, and Re-Rating Potential